<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58572">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01740934</url>
  </required_header>
  <id_info>
    <org_study_id>RCP-012</org_study_id>
    <nct_id>NCT01740934</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea</brief_title>
  <official_title>An Eight-Week, Multi-Site, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Subjects With Rosacea Followed by an Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rock Creek Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rock Creek Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled,
      parallel-group study followed by an eight-week open-label extension to evaluate the safety,
      tolerability, and potential effects of Anatabloc Facial Cream.  The secondary aim is to
      evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild
      to moderate rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>8 to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Collected information of the safety, tolerability and adverse events, and subjective experience related to the use of Anatabloc Cream by subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the appearance of the facial skin</measure>
    <time_frame>8 to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change measured by comparison of questionnaire and rating scores over time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Anatabloc Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily use of active facial cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily use of placebo facial cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anatabloc Cream</intervention_name>
    <arm_group_label>Anatabloc Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <arm_group_label>Placebo Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 25-70 years

          -  diagnosed with mild to moderate rosacea

        Exclusion Criteria:

          -  allergy or sensitivity to the study products or their components

          -  severe rosacea

          -  current use of glucocorticoids, anti-acne products, antibiotics,  topical retinoids,
             or vasoactive drugs

          -  recent oral isotretinoin use

          -  current use of anatabine-containing supplements (ie. Anatabloc, Anatabloc Unflavored,
             CigRx)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Varga, MD</last_name>
    <role>Study Director</role>
    <affiliation>Star Scientific</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Susan H. Weinkle, MD</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lupo Center for Aesthetic &amp; General Dermatology</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diane Berson, MD</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>November 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rosacea</keyword>
  <keyword>anatabine</keyword>
  <keyword>Anatabloc</keyword>
  <keyword>dermatology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
